Botulinum toxin type B
Botulinum toxin type B is a medically relevant serotype with a narrower commercial and clinical footprint than type A. It remains important because it demonstrates that meaningful therapeutic activity can be achieved outside the dominant type A ecosystem.
Role in practice
Section titled “Role in practice”Type B is most often discussed in relation to movement disorders and selected patients who need an alternative to type A-based treatment strategies. Its best-known commercial association is Myobloc / Neurobloc, the main product-level type B node in the current site graph.
How it differs from type A
Section titled “How it differs from type A”Compared with botulinum toxin type A, type B has a smaller product landscape, less aesthetic presence, and a more specialized evidence base. Clinicians and researchers usually evaluate the two serotypes in terms of duration, tolerability, unit systems, and indication-specific fit. Type B also creates a different practical conversation around storage and handling and safety and adverse-effect framing, because the product and tolerability context is not just another version of the dominant type A workflow.
Immunogenicity is one of the reasons this distinction remains clinically interesting, especially when long-term treatment response is being interpreted.
Clinical context
Section titled “Clinical context”Type B is relevant to the broader botulinum toxin topic because it helps define the boundaries of serotype selection. Even when type A remains first-line, understanding type B improves interpretation of comparative pharmacology and product development.